



Animal Health Research Journal

P-ISSN : 2356-7767 On Line-ISSN : 2535-1524

Journal Homepage: <https://animalhealth.ahri.gov.eg/>

Research Paper

Development of an immunochromatographic lateral flow strip test for rapid detection of *Brucella* antigens in clinical specimens

Shaimaa, Abdelall Elsaady*; Waleed, Saad Eldin Shell*; Lubna, F. Farahat**;
Marwa, S. Diab*; Gehad, A. Yousef* and Maha, A. Elshazly*

*Central Laboratory for Evaluation of Veterinary Biologics (CLEVB)-Agricultural Research Center (ARC), Cairo, Egypt

**Veterinary Serum and Vaccine Research Institute (VSVRI)-Agricultural Research Center (ARC), Cairo, Egypt

Received in 8/1/2026
Received in revised from
11/2/2026
Accepted in 12/3/2026

Keywords:

Antigen testing;
Brucella;
Gold nanoparticles;
Lateral flow assay;
Sensitivity and specificity.

Abstract

Brucellosis is an endemic, worldwide zoonotic disease of public health and socioeconomic importance. It mainly infects livestock and human population, with potentially pathogenic species including *Brucella abortus*, *Brucella melitensis*, and *Brucella suis*. Serological methods are used for the diagnosis of brucellosis, resulting in false negatives or false positives, which can cause diagnostic uncertainty. Isolation of *Brucella* species from clinical specimens is the gold standard of diagnosis. Lateral flow immunoassay (LFIA) is a rapid, simple, and economical test that is widely used in the field for fast detection of various analytes. In our study, we generated LFIA strips using anti-smooth *Brucella* lipopolysaccharides (S-LPS) polyclonal antibodies (pAbs) for direct identification of the *Brucella* antigen. A nanogold lateral flow immunoassay-based technique (LFIA) for the detection of *Brucella* antigen was developed and evaluated for diagnostic performance characteristics using *Brucella* and non-*Brucella* cultures and spiked specimens. LFA strips were fabricated by printing anti-bovine antibodies IgG and anti-S-LPS polyclonal antibodies (pAbs) on the control and test lines, respectively. *Brucella* isolation, identification and multiplex PCR were used as the gold standard tests. It was found that the limit of detection (LOD) of the developed LFIA test, when evaluated using the Rev-1 vaccinal strain, indicated that the LFIA strip was able to detect 1×10^4 to 5×10^3 CFU/ reaction. The developed LFIA did not exhibit any cross-reactivity with non-*Brucella* pathogens, and it did not react to rough *Brucella* strains, but gave rise to 100% positive results with all smooth *Brucella* strains and isolates showing 100% selectivity.

Corresponding author: Maha A. Elshazly, Central Laboratory for Evaluation of Veterinary Biologics (CLEVB)-Agricultural Research Center (ARC), Cairo, Egypt
Email address: dr.mahaahmed2006@gmail.com;

Introduction

Brucellosis is an endemic zoonotic disease of public health and socioeconomic importance worldwide. It mainly infects livestock and most domestic animals and also infects the human population with potentially pathogenic species, including *Brucella abortus*, *Brucella melitensis*, and *Brucella suis* (Ghanbari *et al.*, 2020). Current serological methods for the diagnosis of brucellosis include the Rose Bengal test and complement fixation test (OIE, 2018). The Rose Bengal test is a pilot test that is generally used for primary screening, while CFT is used for confirmatory diagnostic characterization. However, all serological tests produce a certain number of false negatives or false positives, which can cause diagnostic uncertainty (Bonfini *et al.*, 2018; Bulashev and Eskendirova, 2023). The isolation of *Brucella* species from microbiological cultures is the gold standard for the laboratory diagnosis of brucellosis (Streva *et al.*, 2024).

Lateral flow immunoassay (LFIA) is a rapid, simple, and economical test that is widely used in the field for fast detection of various analytes (Ge *et al.*, 2021). It is a simplified model of IELISA consisting of a nitrocellulose detection strip that contains *Brucella* antigen as S-LPS or *Brucella* antibody, as well as a *Brucella*-specific capture probe, flanked at one end by a reagent pad that consists of a colloidal gold immune conjugate and flanked at the other end by an absorption pad. Few assays were designed for *Brucella* antigen-based detection. Byzova *et al.* (2012) developed a sandwich format immunochromatographic assay for detecting *Brucella* antigen (smooth *Brucella* lipopolysaccharide (S-LPS)). The LFIA assay is simply carried out by the addition of the sample (serum, specimens, etc.) directly into the sample pad, followed by the addition of test liquid to the buffer pad. The result is visually read within 5 to 15 minutes. The assay is based on the binding of specific antibodies or antigens present in the clinical specimen to the antigen, such as LPS or polyclonal antibodies against the antigen, respectively, and the staining of the bound antibodies or antigens by a colloidal gold-labeled antibody conjugate (Saavedra *et al.*, 2019).

Thus, in our proposed study, we generated

LFIA strips using anti-smooth *Brucella* LPS pAbs to detect intact whole *Brucella* antigen cells for rapid and accurate detection of brucellosis. This LFIA was evaluated and validated for its LOD, sensitivity, specificity, performance, and cross-reactivity using *Brucella* and non-*Brucella* cultures and spiked specimens. *Brucella* isolation and identification, and multiplex PCR were used as the gold standard tests.

Materials and Methods

Bacterial strains and specimen types

Vaccine strains: Strain-19 and RB51 (*B. abortus* biovar 1) and Rev-1 (*B. melitensis* biovar 1) (CZ veterinaria S.A., Pontevedra, Spain).

References strains: 544 (*B. abortus* biovar 1), 16M (*B. melitensis* biovar 1), ETHER (*B. melitensis* biovar 3), REO198 (*Brucella ovis*), and *Brucella suis* 1330 (*B. suis* biovar 1) were kindly supplied by Prof. Dr. J.M. Blasco, CITA Institute, Zaragoza, Spain. Additionally, S99 (*B. abortus* biovar 1) was kindly supplied by the Veterinary Serum and Vaccine Research Institute (VSVRI).

Field isolates: Twenty-five Egyptian field isolates were recovered from different animal species and kindly supplied by Prof. Dr. Ashraf Sayour and Prof. Dr. Waleed Shell. Were identified serologically, biochemically, and via a Bruce-Ladder multiplex PCR assay (López-Goñi *et al.*, 2008, and Shell *et al.*, 2013, OIE, 2018). Twenty-two of these 25 isolates were *Brucella melitensis* biovar 3, and the other three field isolates were *Brucella abortus*.

Other bacteria: *Yersinia enterocolitica* O9, *Escherichia coli* O157:H7, and *Salmonella* serovars of Kauffmann-White Group N as cross-reacting bacteria with serological tests used for the diagnosis of *Brucella*.

Using a colony count equal to the standardized LOD determined in this study, A spiked sample is prepared by adding a *Brucella* field isolate to *Brucella*-free heparinized bovine serum and ground *Brucella*-free bovine lymph nodes in PBS (matrix) (Dong *et al.*, 2016). LOD is detected by an initial study, which was performed to determine the detectable range (colony forming unit/LFIA sample = 40µl) in the spiked specimens and pure *Brucella* culture. The Rev-1 strain was selected and used in

the determination of LOD. These spiked samples are used in validation assay experiments to determine the selectivity of the method and identify matrix effects.

Synthesis of nanogold (40 nm): (Aboelqassem *et al.*, 2022 and Frens, 1973)

One milliliter of a 1% aqueous HAuCl₄ solution was added to 100 mL of deionized water, then boiled with 1.5 mL of 1% sodium citrate while stirring. The mixture turned red within 2 minutes, boiled for 15 minutes, cooled, and stored at 4°C. Additional deionized water was added to reach a total volume of 100 mL, and 0.02% sodium azide was incorporated into the colloidal gold before storage at 4°C. The gold colloids' particle diameter was analyzed using transmission electron microscopy (TEM, H-7650).

Preparation of smooth Brucella lipopolysaccharide (S-LPS)

In-house-prepared smooth lipopolysaccharide (S-LPS, hot Saline Extract) was prepared from *Brucella abortus* S99 according to Alton *et al.* (1988) and Plackett *et al.* (1976).

Preparation of Rabbit IgG anti-LPS (Aboul-Ella *et al.*, 2023, Fishman and Berg, 2018b, Dos Santos *et al.*, 1989):

Animals were obtained from the laboratory animal house in the Central Laboratory for Evaluation of Veterinary Biologics (CLEVB).

1. Rabbit inoculation of LPS

For priming immunization, a stable S-LPS emulsion antigen was created by combining equal volumes of complete Freund's adjuvant (CFA) and LPS antigens at 2 mg/kg body weight, mixed for 20 minutes until achieving a milky white emulsion, then incubated overnight at 6°C. For boosting immunization, a similar process was used, substituting incomplete Freund's adjuvant (IFA) for CFA. Both emulsions were inoculated under aseptic conditions in two 2 kg white male New Zealand rabbits for the production of LPS pAbs.

2. Rabbit IgG purification:

Rabbit IgG was purified from serum pooled five days post-booster with Brucella S-LPS. After adding caprylic acid and stirring, the mixture was centrifuged, and supernatants

were dialyzed overnight against PBS. Immunoglobulin concentrations, measured post-dialysis, ranged from 2 to 2.4 g/dl, with a subsequent dilution to 1 mg/ml using ultrapure water. Brucella-specific polyclonal antibodies (pAbs) were formed by pooling equal volumes of IgG antibodies against LPS. An agar gel precipitation test was then optimized to evaluate these pAbs.

Preparation of IgY against LPS (Amro *et al.*, 2018):

1. Immunization of chicken and egg collection

Five chickens of Single Comb White Leghorns that were 6 months old were inoculated S/C with 0.1 ml of 5 mg of S-LPS. Three doses were administered with a two-week interval between the first and the second vaccination and one week between the second and the third vaccination. To detect the best quantities of IgY antibodies, Eggs were collected from the immunized chickens between specific time intervals of the three doses. Samples were then stored at 4 °C until the extraction of the IgY from the immunized egg yolk.

2. Extraction of chicken IgY antibodies from immunized Single Comb White Leghorns egg yolk

This protocol outlines the extraction of immunoglobulin Y (IgY) using Polyethylene Glycol (PEG 6000) precipitation from egg yolk. Initially, the eggshell is cracked, and the yolk is filtered to remove egg white. After measuring the yolk volume, phosphate-buffered saline (PBS) is added, followed by PEG 6000, and the mixture is vortexed and centrifuged. The process is repeated with an increment in PEG concentration. The final pellet is dissolved in PBS and transferred to a dialysis membrane to eliminate salt, followed by overnight stirring in dialysis buffer. The sample's successful IgY extraction is confirmed through SDS-PAGE and Western blot.

Conjugation of nanogold with rabbit IgG anti-S-LPS (Sayed *et al.*, 2023):

Using 0.02M K₂CO₃, the colloid gold solution was adjusted to pH 8.5. With gentle stirring, 100ul rabbit IgG anti S-LPS (1mg/0.1ml of 0.05% NaCl buffer) were added drop-wise to

10ml of pH-adjusted colloid gold solution. The mixture was gently mixed for 10min and then blocked using 1% (m/v) final concentration of polyethylene glycol (PEG - 20,000 kDa), followed by stirring for an additional 15 min and centrifugation for 30 min at 10,000 g. The pellets were suspended in 1ml dilution buffer [20mM Tris/HCl buffer (pH 8.2) containing 3% (w/v) sucrose, 1% (w/v) BSA, and 0.02% sodium azide then stored at 4°C until used.

Preparation of the immunochromatographic lateral flow kit (Sayed *et al.*, 2023 and Ajaikumar *et al.*, 2021):

1. Sample pad (Ahlstrom)

Sample pad is made of glass fiber and was saturated with PBS solution of pH 7.2 containing blockers like bovine serum albumin (1%), casein (0.1–0.5%), gelatin (0.05–0.1), and surfactants like Triton X-100 (<0.05%) and Tween-20 (<0.05%) and dried at 37°C. Then it was kept under dry conditions at room temperature until used.

2. The conjugate pad (Ahlstrom):

The conjugate pad was made of glass fiber and was treated with 0.1% Tween-20 for 10 min and dried at 60°C. The prepared glass fiber was cut into sections (4cm×0.5 cm), and then saturated with 150µl of colloidal gold probe consisting of rabbit IgG anti-Brucella S-LPS conjugated with nanogold. The conjugate pad was dried for 1 hour at 37°C and stored under dry conditions at 4°C until used.

3. Nitrocellulose membrane (BIODOT - XYZ-3):

Two lines were dispensed on the nitrocellulose membrane (25mm×300mm) first line was the IgY anti LPS (1.5mg/0.1ml) which was dispensed on the test (T) line (1µl per 1 cm line) and the second line was for goat antirabbit IgG immunoglobulin (1mg/0.1ml) which was dispensed on the control line C (1µl per 1 cm line) using IsoFlow™ Lateral Flow Reagent Dispenser, USA.

4. Cutting the membrane:



After that, the membrane was covered with the top laminate and cut into 0.5-cm-width test strips by using an automated cutter (Guillotino

Cutter GCI1800),

Interpretation of the test

This LFIA is coated with two lines (a control line and a test line). If the specimen contains Brucella antigens, they will bind to the Brucella antibodies coated on the test line region (T), generating a colored line, indicating a positive result. If Brucella antigens are not present in the samples, the test line region will not generate any colored line, indicating a negative result. As a control, a colored line will always appear in the control line region (C), either in negative or positive specimens, indicating that the test procedure has been carried out in a proper manner.

In case of positive results, two colored lines will appear, and a colored line should always appear in both the control (C) line and in the test line (T) region. A positive result indicates the detection of Brucella antigen in the specimen, as shown in Figure 1 (A). But in the case of negative results, a colored line appears only in the control region, while a colorless test line appears, as shown in Figure 1 (B). Both A and B are valid results. Invalid results, as shown in Figure 1 (C), occur when a colored control line does not appear. Interpretation and reading of the test were performed within 5-10 minutes (Fig. 2



Gold standard tests

Isolation and detection of *Brucella* recovered from clinical specimens, and its identification, traditionally and by multiplex PCR assay (BRUCE-LADDER) were used in this study as gold standard tests. All procedures involving *Brucella* were conducted under biosafety level 2 (BSL-2) conditions due to its zoonotic risk. Laboratory work was performed using a Class II biosafety cabinet, with strict use of personal

protective equipment (PPE) and aseptic techniques. All infectious materials and waste were properly disinfected or autoclaved before disposal, and only trained personnel handled the samples to minimize the risk of laboratory-acquired infection **OIE (2018)**.

Results

All strains in this study are identified traditionally and by the BRUCE-LADDER assay, as shown in Photo (1)




Photo. (1). Bruce-ladder multiplex PCR profile of vaccine, reference and locally-isolated *Brucella* strains and *Yersinia enterocolitica* O9. M = 100 base pair (bp) DNA ladder (Fermentas). Lane 1 are *Yersinia enterocolitica* O9, Lanes 2: Amplification products of *B. ovis* REO198, lane 3: *B. abortus* RB51 vaccine strain, lane 4: PCR profile of all *Brucella abortus* isolates, lane 5: *B. melitensis* Rev1 vaccine strain, lane 6: PCR profile of all *Brucella melitensis* isolates, lane 7: *B. abortus* S19 vaccine strain

LOD using different matrices:

The LOD was evaluated using direct bacterial culture of different *Brucella melitensis* biovar 1 (Rev-1) matrices. In this study, the LOD was determined by using eight dilutions of *Brucella melitensis* biovar 1 (Rev-1) with wide range of colony counts ranging from 5×10^7 to 5×10^1 CFU/40 μ l (sample dose) and then with seven

dilutions of *Brucella melitensis* biovar 1 (Rev-1) with narrow range of colony counts ranging from 1×10^6 to 1×10^3 CFU/40 μ l prepared by ten and double serial dilution respectively in PBS. The limit of detection of *Brucella* by this assay ranged from 1×10^4 to 5×10^3 CFU/40 μ l (Figure 3 and 4).




Fig. (3) LOD of LFIA assay using serially diluted culture *Brucella melitensis* biovar 1, vaccine strain (rev. 1). 1–7 represented the colony count of 5×10^7 , 5×10^6 , 5×10^5 , 5×10^4 , 5×10^3 , 5×10^2 , 5×10^1 CFU per sample and last strip is *Brucella* free culture.




Fig. (4). LOD of LFIA assay using serially diluted culture *Brucella melitensis* biovar 1, vaccine strain (rev. 1). 1–7 represented the colony count of 1×10^6 , 5×10^5 , 1×10^5 , 5×10^4 , 1×10^4 , 5×10^3 , 1×10^3 CFU per sample.

Sensitivity of LFIA to smooth Brucella strains

All *Brucella* reference strains and field isolates were investigated using the developed LFIA for evaluation of assay sensitivity. Six out of the 31 strains are reference strains, where the other 25 isolates are Egyptian field isolates be-

long to different *Brucella* species and biovars, and all of these strains and isolates are smooth in nature. Additionally, 15 specimens spiked with field isolates were used, with 5 clinical specimens free from brucellosis used as a negative control (Figures 5 and 6) and (Table 1).




Fig. (5). Sensitivity of LFIA assay using direct culture of smooth *Brucella* strains: *Brucella abortus* biovar 1 (S544), *Brucella suis* biovar 1 (S1330) and *Brucella melitensis* biovar 1 (S16M). All strains were in a colony count of LOD (1×10^4 to 5×10^3 CFU / sample).




Fig. (6). Sensitivity of LFIA assay using direct culture of smooth and rough *Brucella* vaccine strains: rough *Brucella abortus* biovar 1 (SRB51), smooth *Brucella suis* biovar 1 (S19) and smooth *Brucella melitensis* biovar 1 (Rev. 1). All strains were in a colony count of $1-5 \times 10^8$ CFU / sample.

Table (1). Sensitivity of the developed LFIA against smooth Brucella strains

Strain/Specimen Type	Number Tested	LFIA Result	Sensitivity
<i>Brucella abortus</i> isolates	3	Positive	100%
<i>Brucella melitensis</i> isolates	22	Positive	100%
Smooth reference strains	6	Positive	100%
Spiked clinical specimens	15	Positive Starting from 1×10^4 CFU / sample	100%
Negative control specimens	5	Negative	—

Specificity against rough Brucella strains

Specificity was evaluated against rough Brucella strains using two main rough strains, which are *Brucella abortus* biovar 1 (RB51)

vaccinal strain and *Brucella ovis* REO198 in colony count ranging from $1-5 \times 10^8$ CFU/ 40 μ l (Figure 7).



Fig. (7). Specificity of LFIA assay using direct culture of rough Brucella strains: (1) *Brucella abortus* biovar 1 (vaccine strain RB51), (2) *B. ovis* REO198 both were in a colony count of $1-5 \times 10^8$ CFU/ sample.

Specificity against other Gram-negative bacteria (False positive results of LFIA)

In this assay, specificity was evaluated using cultures of other gram-negative bacteria, especially *Y. enterocolitica* O:9, Salmonella serovars of Kauffmann-White Group N and *E. coli* O157:H7, with known colony counts ranging from $1-5 \times 10^8$ CFU/ 40 μ l to check the presence of cross reactions and false positive results (Table 2). These Gram-negative bacteria are the most important cross-reactive bacte-

ria with Brucella. None of the gram-negative bacteria used in this study reacted with anti-Brucella S-LPS polyclonal antibodies (pAbs). This indicates that, based on the analytical specificity determination, no cross reactions to any non-Brucella strains were detected (Figure 8).




Fig. (8). Specificity of LFIA assay using direct culture of non-Brucella strains: (1) *Y. enterocolitica* O:9, (2) *Salmonella* serovars of Kauffmann-White Group N and (3) *E. coli* O157:H7 and control positive (4) smooth *Brucella* strain (S16M).

The results of LFA with non-Brucella strains and rough *Brucella* strains demonstrated that this LFIA assay displayed high selectivity for

the detection of smooth *Brucella* strains with 100% specificity and 100% sensitivity.

Table (2). Specificity and cross-reactivity of the developed LFIA

Tested Organism	Strain Type	LFIA Result	Cross-reactivity
<i>Brucella abortus</i> RB51	Rough <i>Brucella</i> strain	Negative	None
<i>Brucella ovis</i> REO198	Rough <i>Brucella</i> strain	Negative	None
<i>Yersinia enterocolitica</i> O:9	Non- <i>Brucella</i> bacterium	Negative	None
<i>Salmonella</i> Group N	Non- <i>Brucella</i> bacterium	Negative	None
<i>Escherichia coli</i> O157:H7	Non- <i>Brucella</i> bacterium	Negative	None

Discussion

The present study demonstrated that the developed lateral flow immunoassay (LFIA) strip is capable of detecting smooth *Brucella* antigens with a detection limit ranging from 5×10^3 to 1×10^4 CFU/40 μ l of *Brucella melitensis* biovar 1 (Rev-1). This level of sensitivity indicates that the assay is suitable for detecting moderate bacterial loads in clinical samples and may be useful in early-stage infections where bacterial counts are still limited. The achieved sensitivity can be attributed to the use of specific anti-*Brucella* S-LPS polyclonal antibodies in combination with colloidal gold nanoparticles,

which enhance both antigen–antibody binding efficiency and visual signal detection.

In terms of specificity, the developed LFIA showed no cross-reactivity with non-*Brucella* gram-negative bacteria included in this study. This high specificity may be explained by the selective targeting of smooth lipopolysaccharide (S-LPS), which is a major antigenic determinant unique to smooth *Brucella* strains. This finding is in agreement with **Byzova *et al.* (2012)**, who reported that their immunochromatographic assay showed no cross-reactions with a wide range of bacterial species even at high concentrations. Similarly, **Prakash *et al.***

(2021) demonstrated that LFIA could specifically detect *Brucella* isolates without interference from other pathogens. However, in contrast to the present findings, **Lu *et al.* (2023)** reported minor cross-reactivity with *Yersinia enterocolitica* O:9, which may be attributed to structural similarities in LPS antigens. This suggests that assay specificity can be influenced by antigen selection and antibody design.

The diagnostic performance of the LFIA developed in this study is comparable to other serological and molecular diagnostic methods. **Prakash *et al.* (2021)** reported sensitivity values ranging from 78.57% to 80% and specificity values between 93.07% and 94% when LFIA was compared to culture and PCR methods. Likewise, **Amahyel *et al.* (2019)** found that LFIA showed high sensitivity and specificity across different animal species, with values approaching those of established tests such as ELISA and the Rose Bengal Test (RBT). In addition, **Ge *et al.* (2021)** reported no significant difference between LFIA and ELISA in diagnostic accuracy, although LFIA demonstrated slightly higher sensitivity in some cases. More recently, **Lu *et al.* (2023)** developed a nanoparticle-based LFIA system that achieved very high sensitivity (98.33%) and specificity (100%), highlighting the potential for further enhancement of LFIA performance through nanotechnology.

One of the major advantages of the LFIA developed in this study is its rapid detection capability. The assay provides results within a short time without requiring complex instrumentation or highly specialized laboratory conditions. This makes it particularly suitable for field applications and routine diagnostic laboratories with limited resources. This observation is consistent with **Amahyel *et al.* (2019)**, who emphasized the practicality and ease of use of LFIA for large-scale screening in veterinary settings.

Despite the effectiveness of colloidal gold nanoparticles used in this study, alternative labeling systems such as latex microspheres have been reported to offer improved sensitivity. **Li *et al.* (2019a)** demonstrated that latex-based LFIA systems can produce stronger signals and lower detection limits compared to traditional

gold-based assays. However, both systems remain widely used and effective, and the choice between them depends on the required sensitivity and application context.

In addition to immunoassays, molecular diagnostic approaches such as multiple cross displacement amplification (MCDA) have shown promising results for *Brucella* detection. This technique targets species-specific genes such as *Bscp31* and can be combined with lateral flow biosensors to achieve rapid and highly specific detection. **Li *et al.* (2019b)** and **Huang *et al.* (2020)** reported 100% specificity with no cross-reactions when using this approach. However, despite its high accuracy, MCDA requires more technical expertise and laboratory setup compared to LFIA, which remains a simpler and more accessible method.

Overall, the findings of the present study indicate that the developed LFIA strip is a reliable and efficient diagnostic tool for the detection of smooth *Brucella* strains. It combines acceptable sensitivity with high specificity and offers significant advantages in terms of speed, simplicity, and ease of use. Future improvements, particularly through the use of more sensitive labeling materials such as latex microspheres or advanced nanoparticles, may further enhance its diagnostic performance and contribute to better control and eradication of brucellosis.

Acknowledgments

The authors acknowledge their respective central laboratory and institute for their cooperation.

Ethics approval and consent to participate

This study was conducted in accordance with guidelines set by the Institutional Animal Care and Use Committee at the Laboratory Animal Resources isolation facilities of Central Laboratory for Evaluation of Veterinary Biologics-Agriculture Research Center. IACUC approval No. (ARC-CLEVB-35-25). No anesthesia or euthanasia protocols were employed for animals involved in this study, as all animal-dependent methodological procedures were categorized as either no-pain or low-pain procedures that can be ethically performed on a conscious and alive animal.

Authors' contributions

The contribution of the authors was as follows; W.S. and M.E.; design of experiment and laboratory work, Sh.A.; preparing required strips and writing its data; M.E. and L.F.; preparing of strains for laboratory work, W.S.; writing the original draft, M.D.; review and editing, G.Y.; collecting reviews and interpretation, Sh. A., W.S., L.F., M.D., G.Y., and M.E. All authors have read and approved the final manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Aboelqassem, Z.M.; Ibrahim, H.M.; Sayed, R.H.; Sobhy, H.M. and Hekal, S.H.A. (2022).** Preparation and evaluation of a lateral flow immunochromatographic nanogold diagnostic kit for brucellosis in sheep. *Veterinary World*. 15(11): 2658–2664. doi: [www.doi.org/10.14202/vetworld.2022.2658-2664](https://doi.org/10.14202/vetworld.2022.2658-2664)
- Aboul-Ella, H.; Hamed, R. and Abo-Elyazeed, H. (2023).** Development, preparation, and evaluation of a novel dotted lateral flow immunochromatographic kit for rapid diagnosis of dermatophytosis *Scientific Reports*. 13:248 <https://doi.org/10.1038/s41598-023-27443-4>
- Ajaikumar, S.; Thushara, T.; Riji, T.; RHEMA, E.T. and Jofy, K.P. (2021).** Vasudevan DM. Development and Troubleshooting in Lateral Flow Immunochromatography Assays *Indian J Clin Biochem*. 36(2): 208–212. doi:10.1007/s12291-020-00887-5
- Alton, G.G.; Jones, L.M.; Angus, R.D. and Verger, J.M. (1988).** Techniques for the Brucellosis Laboratory. Institute National de la Recherche Agronomique, Paris. 1988.
- Amahyel, M.G.; Wilson J.B.; M, J.M.; Luci, D.P.; Henk, L.S.; Reuben, A.O.; Jose', M.B.; Ignacio, M. and Pilar, M.M. (2019).** Comparative performance of lateral flow immunochromatography, ELISA and Rose Bengal tests for the diagnosis of cattle, sheep, goat and swine brucellosis. *PLoS Negl Trop Dis*. 13(6): e0007509, doi: 10.1371/journal.pntd.0007509
- Amro, W.A.; Wael, A. and Fawzi, A. (2018).** Production and purification of IgY antibodies from chicken egg yolk. *Journal of Genetic Engineering and Biotechnology*. 16:99–103 doi: 10.1016/j.jgeb.2017.10.003
- Bonfini, B.; Chiarenza, G.; Paci, V.; Sacchini, F.; Salini, R.; Vesco, G.; Villari, S.; Zilli, K. and Tittarelli, M. (2018).** Cross-reactivity in serological tests for brucellosis: a comparison of immune response of *Escherichia coli* O157:H7 and *Yersinia enterocolitica* O:9 vs *Brucella* spp. *Veterinaria Italiana*. 54 (2): 107-114. doi: 10.12834/VetIt.1176.6539.2
- Bulashev, A. and Eskendirova, S. (2023).** Brucellosis detection and the role of *Brucella* spp. cell wall proteins. *Vet World*. 16(7): 1390–1399, doi: 10.14202/vetworld. 2023. 1390-1399.
- Byzova, N.A.; Zherdev, A.V.; Eskendirova, S.Z.; Baltin, K.K.; Unysheva, G.B.; Mukanov, K.K.; Ramankulov, E.M. and Dzantiev, B.B. (2012).** Development of Immunochromatographic Test System for Rapid Detection of the Lipopolysaccharide Antigen and Cells of the Causative Agent of Bovine Brucellosis, *Applied Biochemistry and Microbiology*. 48(6):653-61.
- Dong, M.; Fisher, C.; Añez, G.; Rios, M.; Nakhasi, H.L.; Hobson, J.P.; Beanan, M.; Hockman, D.; Grigorenko, E. and Duncan, R. (2016).** Standardized methods to generate mock (spiked) clinical specimens by spiking blood or plasma with cultured pathogens, *Journal of Applied Microbiology*. 120 (4):1119-1129. <https://doi.org/10.1111/jam.13082>
- Dos Santos, M.C.; D'Império Lima, M.R.; Furtado, G.C.; Colletto, G.M.; Kipnis, T.L. and Dias da Silva, W. (1989).** Purification of F(ab')₂ anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. *Toxicon*. 27(3):297-303. doi: 10.1016/0041-0101(89)90177-3.
- Fishman, J.B. and Berg, E.A. (2018).** Ammonium Sulfate Fractionation of Antibodies. *Cold Spring Harb Protoc*. 6. doi: 10.1101/pdb.prot099119.
- Frens, G. (1973).** Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions. *Nature Physical Science*. 241:20-22. <https://doi.org/10.1038/>

- physci241020a0
- Ge, L.; Wang, D.; Lian, F.; Zhao, J.; Wang, Y.; Zhao, Y.; Zhang, L.; Wang, J.; Song, X.; Li, J. and Xu, K. (2021).** Lateral Flow Immunoassay for Visible Detection of Human Brucellosis Based on Blue Silica Nanoparticles. *Front Vet Sci.* 8:771341. doi:10.3389/fvets.2021.771341.
- Ghanbari, M.K.; Gorji, H.A.; Behzadifar, M.; Sane, N.; Mehedi, N. and Bragazzi, N.L. (2020).** One health approach to tackle brucellosis: a systematic review. *Trop Med Health.* 20:48:86. doi: 10.1186/s41182-020-00272-1.
- Huang, T.; Zhang, J.; Sun, C.; Liu, Z.; He, H.; Wu, J. and Geriletu, A. (2020).** Novel Arthropod Host of Brucellosis in the Arid Steppe Ecosystem. *Front Vet Sci.* 7: 566253. <https://doi.org/10.3389/fvets.2020.566253>
- Li, S.; Liu, Y.; Wang, Y.; Chen, H.; Liu, C. and Wang, Y. (2019a).** Lateral flow biosensor combined with loop-mediated isothermal amplification for simple, rapid, sensitive, and reliable detection of *Brucella* spp. *Infect Drug Resist.* 12:2343-2353. doi: 10.2147/IDR.S211644.
- Li, S.; Liu, Y.; Wang, Y.; Wang, M.; Liu, C. and Wang, Y. (2019b).** Rapid Detection of *Brucella* spp. and Elimination of Carryover Using Multiple Cross Displacement Amplification Coupled With Nanoparticles-Based Lateral Flow Biosensor. *Front. Cell. Infect. Microbiol.* 9:78. doi: 10.3389/fcimb. 2019.00078.
- López-Goñi, I.; García-Yoldi, D.; Marín, C.M.; De Miguel, M.G.; Muñoz, P.M.; Blasco, J.M.; Jacques, I.; Grayon, M.; Cloeckert, A.; Ferreira, A.C.; Cardoso, R.; Corrêa de Sá, M.I.; Walravens, K.; Albert, D. and Garin Bastuji, B. (2008).** Evaluation of a multiplex PCR assay (Bruce ladder) for molecular typing of all *Brucella* species, including the vaccine strains. *J. Clin Microbiol.*, 46: 3484-3487. <https://doi.org/10.1128/jcm.00837-08>
- Lu, J.; Li, C.; Zhang, E.; Hou, S.; Xiao, K.; Li, X.; Zhang, L.; Wang, Z.; Chen, C.; Li, C. and Li, T. (2023).** Novel Vertical Flow Immunoassay with Au@PtNPs for Rapid, Ultrasensitive, and On-Site Diagnosis of Human Brucellosis. *ACS Omega.* 8 (32):29534-29542. doi: 10.1021/acsomega.3c03381.
- OIE; World Organization for Animal Health (2018).** Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Available online: <http://www.oie.int/manual-of-diagnostic-tests-and-vaccines-for-terrestrial-animals/> (accessed on 16 February 2018).
- Plackett, P.; Cottew, G.S. and Best, S.J. (1976).** An indirect haemolysis test (IHLT) for bovine brucellosis. *Aust. Vet. J.*, 52: 136-40. doi: 10.1111/j.1751-0813.1976.tb05448.x.
- Prakash, C.; Kumar, B.; Singh, R.P.; Singh, P.; Shrinet, G.; Das, A.; Ashmi, M.; Abhishek Singh, K.P.; Singh, M.K. and Gupta, V.K. (2021).** Development and evaluation of a gold nanoparticle based Lateral Flow assay (LFA) strip test for detection of *Brucella* spp. *Journal of Microbiological Methods.* 184:106185. doi: 10.1016/j. mimet. 2021.106185.
- Saavedra, M.J. S.; Fernandes, C. and Queiroga, C. (2019).** Laboratory Diagnosis of Brucellosis” in *Brucellosis in goats and sheep*”. Editors: Caetano SimõesJC., SaavedraMJ., HunterPA. Publisher: Nova Science Publishers, Inc., New York, USA; P. 151-180.
- Sayed, R.H.; Soliman, R.T. and Elsaady, S.A. (2023).** Development of a lateral flow device for rapid simultaneous multiple detections of some common bacterial causes of bovine mastitis. *J. Adv. Vet. Anim. Res.* 10 (2):292–300. doi: 10.5455/javar.2023.j681
- Shell, W.S.; Khedr, A. and El-Maghraby, A.S. (2013).** Multiple Locus Variable Number Tandem Repeat Analysis (MLVA) for Genotyping of Egyptian *Brucella* Isolates. *Global Veterinaria*, 11 (4): 446-453. doi:10.5829/idosi.gv.2013.11.4.76125
- Streva, V.A.; Weinstein, J.; Jankowski-Romano, C.; Osakwe, N.; Duong, S.; Juretschko, S. and Lemon, J.K. (2024).** The Brief Case: Incidental finding of *Brucella abortus* bacteremia in a patient with urinary tract infection. *J. Clin. Microbiol.*62:e01381-23. <https://doi.org/10.1128/jcm.01381-23>